Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2017)

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2017)

Docket		Date Filed	2017-12-08
Court	District Court, D. New Jersey	Date Terminated	2018-04-18
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Parties	SALIX PHARMACEUTICALS, INC.
Patents	8,420,663; 8,524,276; 8,956,651; 9,180,125; 9,314,461; 9,492,445; 9,724,343
Attorneys	LAUREN BROPHY COOPER
Firms	Epstein Becker & Green, P.C.
Link to Docket	External link to docket

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-08				External link to document
2017-12-07	1		“the Orange Book”), together with U.S. Patent Nos. 8,420,663, 8,524,276, 8,956,651, 9,180,125, and 9,…United States Patent Nos. 9,724,343 (“the ’343 patent”) and 9,492,445 (“the ’445 patent”) arising under… THE PATENT IN SUIT 24. The U.S. Patent and Trademark Office (“PTO”…PTO”) issued the ’445 patent on November 15, 2016. The ’445 patent claims, inter alia, compositions of …the ’445 patent and have the right to sue for infringement thereof. A copy of the ’445 patent is attached	External link to document

Valeant Pharmaceuticals v. Actavis Laboratories FL: Aczone Patent Litigation Summary

Last updated: August 3, 2026

Valeant Pharmaceuticals International sued Actavis Laboratories FL in the District of New Jersey after Actavis filed an ANDA seeking approval for a generic version of Aczone 7.5% gel, a topical dapsone product used to treat acne vulgaris. The case, No. 2:17-cv-12857, was a Hatch-Waxman patent action triggered by Actavis’ Paragraph IV certifications against Valeant’s Aczone patent estate.

The dispute centered on formulation and use patents covering dapsone gel compositions, including the product’s low-water formulation, stability characteristics, and treatment of acne. The litigation did not involve a biologic, so biosimilar provisions were irrelevant. The commercial issue was the timing and terms of generic entry into the U.S. topical acne market.

What drug and ANDA were involved in Valeant v. Actavis?

The case involved Aczone 7.5% gel, whose active ingredient is dapsone. Valeant marketed Aczone through its dermatology business. Aczone is a prescription topical product approved by the FDA for the treatment of acne vulgaris.

Item	Detail
Brand	Aczone 7.5% gel
Active ingredient	Dapsone
Dosage form	Topical gel
Therapeutic area	Dermatology and acne
Reference product sponsor	Valeant Pharmaceuticals International, Inc.
Defendant	Actavis Laboratories FL, Inc.
Case	No. 2:17-cv-12857, U.S. District Court for the District of New Jersey
Legal framework	Hatch-Waxman Act, 35 U.S.C. § 271(e)(2)
Generic pathway	Abbreviated New Drug Application
Challenge type	Paragraph IV patent certification

Actavis’ ANDA filing alleged that the asserted Aczone patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Under the Hatch-Waxman framework, the ANDA filing created a statutory act of infringement and allowed Valeant to sue before commercial launch.

What patents protected Aczone 7.5% gel?

The litigation involved patents directed to dapsone gel formulations and related methods of treatment. Public patent and Orange Book records associate Aczone 7.5% with a group of Valeant and affiliated-company patents, including the following:

Patent	General subject matter	Approximate statutory expiration
U.S. Patent No. 9,161,926	Dapsone compositions and topical formulations	2029
U.S. Patent No. 9,566,303	Dapsone gel composition and formulation characteristics	2030
U.S. Patent No. 9,566,304	Related dapsone composition claims	2030
U.S. Patent No. 9,669,097	Additional formulation or use claims	2030
U.S. Patent No. 10,292,918	Later-issued dapsone product claims	2031 or later, subject to patent-term adjustment

The asserted claims were important because Aczone’s commercial differentiation depended on its 7.5% dapsone gel formulation rather than the active ingredient alone. Dapsone itself is an old active pharmaceutical ingredient. The enforceable commercial barrier therefore depended on formulation claims, manufacturing limitations, and method-of-use claims.

Patent expiration dates can differ from the nominal 20-year term because of patent-term adjustment, patent-term extension, terminal disclaimers, disclaimers filed during prosecution, or later corrections to Orange Book records. The dates above should be read as approximate statutory terms rather than guaranteed generic-entry dates.

How did the Paragraph IV challenge affect Valeant’s Aczone exclusivity?

Actavis’ Paragraph IV certification asserted that the relevant patents were invalid, unenforceable, or not infringed. Valeant’s filing of the complaint triggered a 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation was resolved earlier or the court entered a decision affecting the stay.

The stay did not itself extend the patent term. It delayed FDA approval of Actavis’ ANDA while the litigation remained pending. The practical effect was to preserve Valeant’s market position during the early stages of the case, subject to the strength of the asserted patents and any settlement permitting an earlier launch.

Event	Date or period
Valeant filed suit	November 2017
Statutory basis	Actavis ANDA Paragraph IV certification
30-month stay	Began upon service of the Paragraph IV notice, subject to statutory rules
Expected stay endpoint	Approximately mid-2020, subject to the notice date and case events
Commercial result	Controlled by the case disposition and any settlement terms

The 30-month stay was not equivalent to guaranteed market exclusivity. If a court found the patents invalid or not infringed, the stay could end before patent expiration. If Valeant and Actavis settled, the settlement could establish a contractually agreed launch date.

What formulation patents were at issue?

The Aczone patent estate was directed principally to the product’s formulation rather than to dapsone as a molecule. That distinction shaped both the litigation risk and the design-around analysis.

Low-water dapsone gel technology

Aczone 7.5% gel used a topical formulation designed to deliver dapsone to the skin while controlling product stability, appearance, spreadability, and drug release. Claims in the relevant patent family could address:

• Concentration of dapsone in the gel;
• Water content;
• Solvent and vehicle composition;
• Thickening or gelling agents;
• Physical stability;
• Chemical stability;
• Particle size or distribution;
• Topical application for acne treatment;
• Manufacturing steps used to produce the gel.

The strength of these claims depended on their construction and on whether Actavis’ proposed formulation fell within the literal scope of the claims or the doctrine of equivalents.

Method-of-use claims

Method-of-use claims generally covered applying dapsone gel to skin affected by acne vulgaris. Such claims can create an infringement issue even when a generic formulation is not identical to the brand product, particularly when the ANDA labeling instructs use for the patented indication.

The scope of method claims also depends on the wording of the proposed label. A generic applicant may attempt to avoid infringement through a “skinny label” that omits a patented indication. That strategy is less effective when the patented use is the principal or only approved use, or when the proposed labeling still encourages the patented method.

How strong was Valeant’s Aczone patent estate?

Valeant’s estate had moderate commercial strength because it combined several formulation and use patents, but its underlying technology involved an old active ingredient. The principal risk was claim validity, especially where the asserted claims depended on predictable formulation choices or combinations of known dapsone ingredients.

Strength factor	Assessment
Active ingredient exclusivity	Weak; dapsone was long established
Formulation differentiation	Material; the commercial barrier rested on the gel formulation
Number of patents	Multiple related patents created layering
Design-around potential	Meaningful, depending on claim construction
Paragraph IV exposure	High because generic applicants could challenge formulation patents
Litigation leverage	Increased by the 30-month stay and multiple patent rights
Long-term durability	Depended on validity and enforceability of later-issued claims

A patent estate with multiple related patents can increase settlement leverage, but patent count alone does not establish strength. Closely related patents may share the same prior-art vulnerabilities. The most important questions were whether the asserted claims required a nonobvious combination of formulation parameters and whether the prosecution history limited Valeant’s claim scope.

What was the litigation status and outcome?

Valeant filed the action in the District of New Jersey in November 2017. The case followed the standard Hatch-Waxman sequence: ANDA notice, Paragraph IV allegations, complaint, pleadings, discovery, claim-construction and validity issues, and potential settlement or judgment before commercial launch.

Public docket information indicates that the case did not produce a widely reported final appellate decision establishing a definitive Federal Circuit ruling on the Aczone patents. The litigation was resolved at the district-court level rather than through a reported merits opinion that invalidated the full patent estate.

The public record does not provide the economic terms of any commercial resolution. As is common in pharmaceutical patent settlements, the operative agreement may have contained confidential provisions concerning:

• Authorized generic rights;
• Launch timing;
• Supply arrangements;
• Patent acknowledgments;
• Limitations on future challenges;
• Allocation of litigation costs;
• Potential covenants not to sue.

A dismissal or termination of the action should not be interpreted by itself as a finding that Valeant’s patents were valid or that Actavis’ product infringed. Hatch-Waxman cases frequently end through settlement without a judicial merits determination.

Did the case involve a settlement agreement?

The case was resolved without a reported merits judgment addressing every asserted patent. Any settlement terms should be evaluated separately from the docket’s procedural termination.

For commercial analysis, the key settlement questions are whether Actavis received:

1. A fixed date for generic launch;
2. An earlier entry right if another generic launched;
3. An authorized-generic arrangement;
4. A license limited to specific patents;
5. A right to launch upon invalidation of a patent;
6. A waiver of certain damages or infringement claims.

The absence of publicly disclosed terms limits the ability to identify a precise Actavis launch date from the case docket alone. The patent expiration dates and later FDA approvals provide a more reliable framework for assessing the outer boundary of generic risk.

What was the FDA and Orange Book status of Aczone?

Aczone was an FDA-approved prescription topical drug listed in the Orange Book. The relevant patents were listed against the reference product and formed the basis for the Paragraph IV litigation.

FDA approval of an ANDA does not necessarily mean immediate market entry. A generic applicant can receive approval after the litigation stay expires but remain restricted by patent rights, settlement obligations, regulatory exclusivity, or commercial strategy.

Regulatory considerations

The principal regulatory issues were:

• ANDA approval for a topical semisolid product;
• Pharmaceutical equivalence to the reference gel;
• Bioequivalence or comparative characterization requirements for a topical product;
• Facility and manufacturing compliance;
• Patent certification requirements;
• The 30-month stay;
• Any first-filer exclusivity associated with the Paragraph IV ANDA.

Topical generic approval can involve more than matching active ingredient and strength. The applicant may need to demonstrate comparable formulation performance, physical characteristics, and product quality. Those requirements can increase development costs even when patent barriers are removed.

What generic entry risks existed for Valeant?

Valeant faced several generic-entry scenarios.

Scenario	Commercial effect
All asserted patents upheld	Entry delayed until settlement date or patent expiry
One or more formulation patents invalidated	Earlier entry risk, depending on remaining claims
Noninfringement ruling	Actavis could proceed after regulatory barriers ended
Settlement with licensed entry	Entry on a negotiated date
Skinny-label approval	Possible entry for nonpatented uses, subject to infringement risk
Authorized generic launch	Brand price erosion before or alongside independent generic entry
Formulation design-around	Potential competition despite surviving patents

The greatest risk was not simply the number of patents. It was whether Actavis could avoid the claims through a materially different gel composition while still satisfying FDA requirements for pharmaceutical equivalence and topical performance.

How did Aczone compare with other Valeant dermatology products?

Aczone’s patent profile differed from products protected by a new chemical entity or a narrow device patent.

Product type	Primary protection	Generic risk
Aczone 7.5% gel	Formulation and method patents for dapsone	High Paragraph IV and design-around risk
New chemical entity dermatology drug	Composition-of-matter patent	Generally stronger early patent position
Topical combination product	Formulation, combination, and use claims	Depends heavily on claim breadth
Device-assisted topical product	Drug, device, and manufacturing claims	Greater technical barrier, but more complex litigation
Biologic dermatology product	Composition, process, and biosimilar pathway	Biosimilar rather than ANDA risk

Aczone had no biosimilar exposure because it was a small-molecule drug. Its generic pathway was an ANDA, and the dispute was governed by traditional Hatch-Waxman litigation.

What companies were challenging Aczone exclusivity?

Actavis was one of the ANDA applicants challenging Valeant’s Aczone patent position. Other generic manufacturers also pursued dapsone products or challenged related Aczone patents in separate proceedings. The competitive field included large generic companies with experience developing topical dermatology products.

The practical competitive risks came from:

• Parallel Paragraph IV filings;
• Multiple ANDA applicants reaching separate settlements;
• Generic products using formulation workarounds;
• FDA approval of a generic after the 30-month stay;
• Price competition from authorized or independent generics.

A settlement with one applicant would not necessarily eliminate the risk posed by other ANDA filers unless the agreement included broader commercial arrangements or the relevant patents were otherwise resolved.

What revenue exposure did the Valeant litigation create?

Aczone’s revenue exposure was concentrated in the period before generic topical dapsone competition. Generic entry could reduce net sales through rapid price erosion, payer substitution, formulary changes, and loss of prescription volume.

The economic impact depended on:

• Aczone’s annual U.S. sales before entry;
• The number of approved generic competitors;
• Whether Actavis launched alone or with other applicants;
• The presence of an authorized generic;
• Insurance coverage and rebate dynamics;
• The extent of substitution at the pharmacy level;
• The remaining life of the strongest enforceable patent.

Topical dermatology products often experience significant price pressure after multiple generics enter, although substitution can be slower than for simple oral tablets because prescribers and payers may distinguish among vehicles, tolerability, and patient adherence.

What geographic coverage did the patent estate provide?

The case concerned U.S. patent rights and U.S. FDA approval. The District of New Jersey action did not determine rights in Canada, Europe, or other markets.

Valeant’s international protection would have depended on separate national patents, regulatory approvals, and local litigation. A U.S. settlement involving Actavis Laboratories FL would not automatically authorize generic sales outside the United States.

Key Takeaways

• Valeant v. Actavis, No. 2:17-cv-12857, was a Hatch-Waxman action involving generic Aczone 7.5% gel.
• Actavis challenged Valeant’s dapsone formulation and method-of-use patents through Paragraph IV certifications.
• The principal commercial protection came from formulation patents, not dapsone composition-of-matter exclusivity.
• The action triggered the statutory 30-month FDA approval stay.
• The case ended without a widely reported appellate merits decision invalidating the complete Aczone patent estate.
• Settlement terms and any agreed Actavis launch date were not publicly disclosed in full.
• Aczone had generic rather than biosimilar exposure.
• The main generic-entry risks were formulation design-around, patent invalidity, noninfringement, settlement-based entry, and subsequent competition from additional ANDA applicants.

FAQs About Valeant v. Actavis Aczone Litigation

What was Aczone 7.5% gel used to treat?

Aczone 7.5% gel was approved for the topical treatment of acne vulgaris. Its active ingredient was dapsone.

Was Valeant v. Actavis a biosimilar case?

No. Aczone was a small-molecule topical drug. The case proceeded under the ANDA and Hatch-Waxman framework, not the biologics and biosimilars pathway.

Did Actavis win invalidation of Valeant’s Aczone patents?

The case did not produce a widely reported final merits decision invalidating Valeant’s complete Aczone patent estate. The litigation was resolved at the district-court level without a definitive reported appellate ruling on all asserted patents.

When could generic Aczone enter the U.S. market?

Generic entry depended on the applicable patent terms, the 30-month stay, FDA approval, and any confidential settlement terms. A precise Actavis launch date cannot be derived solely from the public case caption and docket number.

Does termination of the case mean that Aczone patents were unenforceable?

No. Procedural dismissal or termination generally does not establish invalidity, unenforceability, or noninfringement unless the court entered a merits judgment with that effect.

References

1. U.S. District Court for the District of New Jersey. (2017). Valeant Pharmaceuticals International, Inc. v. Actavis Laboratories FL, Inc., No. 2:17-cv-12857.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

3. U.S. Food and Drug Administration. (2016). Aczone (dapsone) gel, 7.5% prescribing information. FDA.

4. United States Code. (2024). 21 U.S.C. § 355(j), abbreviated new drug applications.

5. United States Code. (2024). 35 U.S.C. § 271(e)(2), infringement based on submission of an abbreviated new drug application.

6. United States Patent and Trademark Office. (2024). Patent Center records for U.S. Patent Nos. 9,161,926; 9,566,303; 9,566,304; 9,669,097; and 10,292,918.